The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Radioimmunotherapy Market 2024 by Company, Regions, Type and Application, Forecast to 2029

Global Radioimmunotherapy Market 2024 by Company, Regions, Type and Application, Forecast to 2029

Publishing Date : Sep, 2023

License Type :
 

Report Code : 1772537

No of Pages : 113

Ask Your Query

Synopsis
The global Radioimmunotherapy market size was valued at USD 1073 million in 2022 and is forecast to a readjusted size of USD 3159.2 million by 2029 with a CAGR of 16.7% during review period.

Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.

Global 5 largest Companies of Radioimmunotherapy are Novartis, Bayer, China Isotope & Radiation, Curium Pharmaceuticals and Aurobindo Pharma, which make up over 99%. Among them, Novartis is the leader with about 85% market share. North America is the largest market, with a share about 51%, followed by Europe and Asia-Pacific, with the share about 33% and 14%. In terms of product type, Beta-emitting occupy the largest share of the total market, about 85%. And in terms of product Application, the largest application is Solid Tumor, followed by Non Hodgkin Lymphoma.

The Global Info Research report includes an overview of the development of the Radioimmunotherapy industry chain, the market status of Solid Tumor (Beta-emitting, Targeted Alpha Therapy), Non Hodgkin Lymphoma (Beta-emitting, Targeted Alpha Therapy), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Radioimmunotherapy.

Regionally, the report analyzes the Radioimmunotherapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Radioimmunotherapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Radioimmunotherapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Radioimmunotherapy industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Beta-emitting, Targeted Alpha Therapy).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Radioimmunotherapy market.

Regional Analysis: The report involves examining the Radioimmunotherapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Radioimmunotherapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Radioimmunotherapy:

Company Analysis: Report covers individual Radioimmunotherapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Radioimmunotherapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Solid Tumor, Non Hodgkin Lymphoma).

Technology Analysis: Report covers specific technologies relevant to Radioimmunotherapy. It assesses the current state, advancements, and potential future developments in Radioimmunotherapy areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Radioimmunotherapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Radioimmunotherapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type

  • Beta-emitting
  • Targeted Alpha Therapy

Market segment by Application

  • Solid Tumor
  • Non Hodgkin Lymphoma

Market segment by players, this report covers

  • Bayer
  • Novartis
  • Lantheus
  • Aurobindo Pharma
  • Mundipharma
  • China Isotope & Radiation
  • Curium Pharmaceuticals
  • Gilead Sciences
  • Clarity Pharmaceuticals
  • Curasight
  • Nordic Nanovector
  • Philogen
  • RadioMedix
  • Telix Pharmaceuticals
  • Orano Med
  • Actinium Pharmaceuticals
  • Y-mAbs Therapeutics
  • Fusion Pharmaceuticals

Market segment by regions, regional analysis covers

  • North America (United States, Canada, and Mexico)
  • Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
  • South America (Brazil, Argentina and Rest of South America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Radioimmunotherapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Radioimmunotherapy, with revenue, gross margin and global market share of Radioimmunotherapy from 2018 to 2023.
Chapter 3, the Radioimmunotherapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Radioimmunotherapy market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Radioimmunotherapy.
Chapter 13, to describe Radioimmunotherapy research findings and conclusion.

Index

1 Market Overview
1.1 Product Overview and Scope of Radioimmunotherapy
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Radioimmunotherapy by Type
1.3.1 Overview: Global Radioimmunotherapy Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Radioimmunotherapy Consumption Value Market Share by Type in 2022
1.3.3 Beta-emitting
1.3.4 Targeted Alpha Therapy
1.4 Global Radioimmunotherapy Market by Application
1.4.1 Overview: Global Radioimmunotherapy Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Solid Tumor
1.4.3 Non Hodgkin Lymphoma
1.5 Global Radioimmunotherapy Market Size & Forecast
1.6 Global Radioimmunotherapy Market Size and Forecast by Region
1.6.1 Global Radioimmunotherapy Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Radioimmunotherapy Market Size by Region, (2018-2029)
1.6.3 North America Radioimmunotherapy Market Size and Prospect (2018-2029)
1.6.4 Europe Radioimmunotherapy Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Radioimmunotherapy Market Size and Prospect (2018-2029)
1.6.6 South America Radioimmunotherapy Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Radioimmunotherapy Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Radioimmunotherapy Product and Solutions
2.1.4 Bayer Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bayer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Radioimmunotherapy Product and Solutions
2.2.4 Novartis Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Lantheus
2.3.1 Lantheus Details
2.3.2 Lantheus Major Business
2.3.3 Lantheus Radioimmunotherapy Product and Solutions
2.3.4 Lantheus Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Lantheus Recent Developments and Future Plans
2.4 Aurobindo Pharma
2.4.1 Aurobindo Pharma Details
2.4.2 Aurobindo Pharma Major Business
2.4.3 Aurobindo Pharma Radioimmunotherapy Product and Solutions
2.4.4 Aurobindo Pharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Aurobindo Pharma Recent Developments and Future Plans
2.5 Mundipharma
2.5.1 Mundipharma Details
2.5.2 Mundipharma Major Business
2.5.3 Mundipharma Radioimmunotherapy Product and Solutions
2.5.4 Mundipharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Mundipharma Recent Developments and Future Plans
2.6 China Isotope & Radiation
2.6.1 China Isotope & Radiation Details
2.6.2 China Isotope & Radiation Major Business
2.6.3 China Isotope & Radiation Radioimmunotherapy Product and Solutions
2.6.4 China Isotope & Radiation Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 China Isotope & Radiation Recent Developments and Future Plans
2.7 Curium Pharmaceuticals
2.7.1 Curium Pharmaceuticals Details
2.7.2 Curium Pharmaceuticals Major Business
2.7.3 Curium Pharmaceuticals Radioimmunotherapy Product and Solutions
2.7.4 Curium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Curium Pharmaceuticals Recent Developments and Future Plans
2.8 Gilead Sciences
2.8.1 Gilead Sciences Details
2.8.2 Gilead Sciences Major Business
2.8.3 Gilead Sciences Radioimmunotherapy Product and Solutions
2.8.4 Gilead Sciences Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Gilead Sciences Recent Developments and Future Plans
2.9 Clarity Pharmaceuticals
2.9.1 Clarity Pharmaceuticals Details
2.9.2 Clarity Pharmaceuticals Major Business
2.9.3 Clarity Pharmaceuticals Radioimmunotherapy Product and Solutions
2.9.4 Clarity Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Clarity Pharmaceuticals Recent Developments and Future Plans
2.10 Curasight
2.10.1 Curasight Details
2.10.2 Curasight Major Business
2.10.3 Curasight Radioimmunotherapy Product and Solutions
2.10.4 Curasight Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Curasight Recent Developments and Future Plans
2.11 Nordic Nanovector
2.11.1 Nordic Nanovector Details
2.11.2 Nordic Nanovector Major Business
2.11.3 Nordic Nanovector Radioimmunotherapy Product and Solutions
2.11.4 Nordic Nanovector Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Nordic Nanovector Recent Developments and Future Plans
2.12 Philogen
2.12.1 Philogen Details
2.12.2 Philogen Major Business
2.12.3 Philogen Radioimmunotherapy Product and Solutions
2.12.4 Philogen Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Philogen Recent Developments and Future Plans
2.13 RadioMedix
2.13.1 RadioMedix Details
2.13.2 RadioMedix Major Business
2.13.3 RadioMedix Radioimmunotherapy Product and Solutions
2.13.4 RadioMedix Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 RadioMedix Recent Developments and Future Plans
2.14 Telix Pharmaceuticals
2.14.1 Telix Pharmaceuticals Details
2.14.2 Telix Pharmaceuticals Major Business
2.14.3 Telix Pharmaceuticals Radioimmunotherapy Product and Solutions
2.14.4 Telix Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Telix Pharmaceuticals Recent Developments and Future Plans
2.15 Orano Med
2.15.1 Orano Med Details
2.15.2 Orano Med Major Business
2.15.3 Orano Med Radioimmunotherapy Product and Solutions
2.15.4 Orano Med Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Orano Med Recent Developments and Future Plans
2.16 Actinium Pharmaceuticals
2.16.1 Actinium Pharmaceuticals Details
2.16.2 Actinium Pharmaceuticals Major Business
2.16.3 Actinium Pharmaceuticals Radioimmunotherapy Product and Solutions
2.16.4 Actinium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Actinium Pharmaceuticals Recent Developments and Future Plans
2.17 Y-mAbs Therapeutics
2.17.1 Y-mAbs Therapeutics Details
2.17.2 Y-mAbs Therapeutics Major Business
2.17.3 Y-mAbs Therapeutics Radioimmunotherapy Product and Solutions
2.17.4 Y-mAbs Therapeutics Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Y-mAbs Therapeutics Recent Developments and Future Plans
2.18 Fusion Pharmaceuticals
2.18.1 Fusion Pharmaceuticals Details
2.18.2 Fusion Pharmaceuticals Major Business
2.18.3 Fusion Pharmaceuticals Radioimmunotherapy Product and Solutions
2.18.4 Fusion Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Fusion Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Radioimmunotherapy Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Radioimmunotherapy by Company Revenue
3.2.2 Top 3 Radioimmunotherapy Players Market Share in 2022
3.2.3 Top 6 Radioimmunotherapy Players Market Share in 2022
3.3 Radioimmunotherapy Market: Overall Company Footprint Analysis
3.3.1 Radioimmunotherapy Market: Region Footprint
3.3.2 Radioimmunotherapy Market: Company Product Type Footprint
3.3.3 Radioimmunotherapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Radioimmunotherapy Consumption Value and Market Share by Type (2018-2023)
4.2 Global Radioimmunotherapy Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Radioimmunotherapy Consumption Value Market Share by Application (2018-2023)
5.2 Global Radioimmunotherapy Market Forecast by Application (2024-2029)
6 North America
6.1 North America Radioimmunotherapy Consumption Value by Type (2018-2029)
6.2 North America Radioimmunotherapy Consumption Value by Application (2018-2029)
6.3 North America Radioimmunotherapy Market Size by Country
6.3.1 North America Radioimmunotherapy Consumption Value by Country (2018-2029)
6.3.2 United States Radioimmunotherapy Market Size and Forecast (2018-2029)
6.3.3 Canada Radioimmunotherapy Market Size and Forecast (2018-2029)
6.3.4 Mexico Radioimmunotherapy Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Radioimmunotherapy Consumption Value by Type (2018-2029)
7.2 Europe Radioimmunotherapy Consumption Value by Application (2018-2029)
7.3 Europe Radioimmunotherapy Market Size by Country
7.3.1 Europe Radioimmunotherapy Consumption Value by Country (2018-2029)
7.3.2 Germany Radioimmunotherapy Market Size and Forecast (2018-2029)
7.3.3 France Radioimmunotherapy Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Radioimmunotherapy Market Size and Forecast (2018-2029)
7.3.5 Russia Radioimmunotherapy Market Size and Forecast (2018-2029)
7.3.6 Italy Radioimmunotherapy Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Radioimmunotherapy Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Radioimmunotherapy Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Radioimmunotherapy Market Size by Region
8.3.1 Asia-Pacific Radioimmunotherapy Consumption Value by Region (2018-2029)
8.3.2 China Radioimmunotherapy Market Size and Forecast (2018-2029)
8.3.3 Japan Radioimmunotherapy Market Size and Forecast (2018-2029)
8.3.4 South Korea Radioimmunotherapy Market Size and Forecast (2018-2029)
8.3.5 India Radioimmunotherapy Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Radioimmunotherapy Market Size and Forecast (2018-2029)
8.3.7 Australia Radioimmunotherapy Market Size and Forecast (2018-2029)
9 South America
9.1 South America Radioimmunotherapy Consumption Value by Type (2018-2029)
9.2 South America Radioimmunotherapy Consumption Value by Application (2018-2029)
9.3 South America Radioimmunotherapy Market Size by Country
9.3.1 South America Radioimmunotherapy Consumption Value by Country (2018-2029)
9.3.2 Brazil Radioimmunotherapy Market Size and Forecast (2018-2029)
9.3.3 Argentina Radioimmunotherapy Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Radioimmunotherapy Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Radioimmunotherapy Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Radioimmunotherapy Market Size by Country
10.3.1 Middle East & Africa Radioimmunotherapy Consumption Value by Country (2018-2029)
10.3.2 Turkey Radioimmunotherapy Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Radioimmunotherapy Market Size and Forecast (2018-2029)
10.3.4 UAE Radioimmunotherapy Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Radioimmunotherapy Market Drivers
11.2 Radioimmunotherapy Market Restraints
11.3 Radioimmunotherapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Radioimmunotherapy Industry Chain
12.2 Radioimmunotherapy Upstream Analysis
12.3 Radioimmunotherapy Midstream Analysis
12.4 Radioimmunotherapy Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Published By : GlobalInfoResearch

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock